X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
CFI-400945 (ocifisertib) is a first-in-class, investigational PLK4 inhibitor. It is being evaluated for the treatment of relapsed/refractory acute myeloid leukemia.
Lead Product(s): CFI-400945,Azacitidine
Therapeutic Area: Oncology Product Name: CFI-400945
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
CFI-400945, a first in class inhibitor of Polo-like kinase 4 (PLK4), for the treatment of adult patients with relapsed or refractory Acute Myeloid Leukemia, has shown encouraging signs of monotherapy activity in AML patients with adverse cytogenetics.
Lead Product(s): CFI-400945,Azacitidine
Therapeutic Area: Oncology Product Name: CFI-400945
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
Proceeds will fund the continued clinical development of CFI-400945, CFI-402257 and CFI-402411, the preclinical development of the Biologics and Cell Therapy platform, as well as general corporate purposes.
Lead Product(s): CFI-400945,Azacitidine
Therapeutic Area: Oncology Product Name: CFI-400945
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sino Biopharmaceutical Limited
Deal Size: $91.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 18, 2021
Details:
The trial is built on the preclinical work demonstrating an association between loss of the tumor suppressor PTEN, a common alteration in this disease setting, and response to CFI-400945.
Lead Product(s): CFI-400945
Therapeutic Area: Oncology Product Name: CFI-400945
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
This multi-center, single-arm, open-label phase 2 trial is designed to assess the efficacy of CFI-400945 given with durvalumab in patients with treatment-resistant TNBC.
Lead Product(s): CFI-400945,Durvalumab
Therapeutic Area: Oncology Product Name: CFI-400945
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
